


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1.-24. (Cancelled)

25. (Currently Amended) ~~The method according to Claim 23, wherein the dermatological condition comprises~~ A method for the treatment of psoriasis, cutaneous atopy, respiratory atopy or gingival hypertrophy comprising administering an effective amount of at least one stilbene compound to a patient in need of such treatment, said at least one stilbene compound having the formula (I):



wherein:

- R₁ represents

(i) the -CH₃ radical,


(ii) the radical -CH₂-O-R₆,

(iii) the radical -O-R₆, or

(iv) the radical -CO-R₇.

wherein the radicals R_6 and R_7 have the meanings given below,

- Ar represents a radical selected from the group consisting of one of the radicals of formulae (a) to (f):



wherein R_8 and R_9 have the meanings given below,

- R_2 and R_3 , which may be identical or different, represent a hydrogen atom or a lower alkyl radical,

- R_4 represents the radical $-(X)_m-(CH_2)_n-Y-(CH_2)_p-R_{10}$,


the values m, n and p and the radicals X, Y and R_{10} having the meanings given below,

- R_5 represents a hydrogen or halogen atom, a lower alkyl radical or a radical

-O- R_6 ,

- R_6 represents a hydrogen atom, a lower alkyl radical or a radical -CO- R_{11} ,

- R_7 represents a hydrogen atom, a lower alkyl radical, a radical -OR₁₂ or a radical



wherein R' and R'', which may be identical or different, represent a hydrogen atom, a lower alkyl radical, a mono- or polyhydroxyalkyl radical, or a phenyl radical optionally substituted with a substituent selected from the group consisting of a halogen atom, a hydroxyl radical, an alkyl radical, a nitro function, a methoxy group and an optionally substituted amine function, or alternatively, taken together, R' and R'' form a heterocycle,

wherein


- m is an integer equal to 0 or 1,
- n is an integer ranging from 1 to 6, inclusive,
- p is an integer ranging from 1 to 6, inclusive,
- X represents O or S(O)_q,
- Y represents O or S(O)_q,
- q is an integer ranging from 0 to 2, inclusive,
- R₈ represents a hydrogen or halogen atom, a lower alkyl radical or a radical
-O-R₆,
- R₉ represents a hydrogen atom, a lower alkyl radical or a radical -CO-R₁₁,
- R₁₀ represents a mono- or polyhydroxyalkyl radical wherein the hydroxyls
are optionally protected in the form of methoxy, ethoxy, acetoxy or acetonide, a
radical -CO-R₇ or a benzyl or phenethyl radical, optionally substituted with a
substituent selected from the group consisting of a halogen atom, a hydroxyl, a nitro
function and a methoxy group,

- R₁₁ represents a lower alkyl radical,

- R₁₂ represents a hydrogen atom, an alkyl radical, an alkenyl radical, a mono- or polyhydroxyalkyl radical in which the hydroxyls are optionally protected in the form of methoxy, ethoxy, acetoxy or acetonide, a phenyl radical optionally substituted with a substituent selected from the group consisting of a halogen atom, a hydroxyl radical, an alkyl radical, a nitro function, a methoxy group and an optionally substituted amine function, or a benzyl or phenethyl radical, optionally substituted with a substituent selected from the group consisting of a halogen atom, a hydroxyl, a nitro function and a methoxy group,

or a salt thereof, or an optical or geometrical isomer thereof.

26. (Currently Amended) ~~The method according to Claim 23, wherein the dermatological condition comprises~~ A method for the treatment of cutaneous psoriasis, mucous psoriasis, unguinal psoriasis, psoriatic rheumatism, eczema, respiratory atopy or gingival hypertrophy comprising administering an effective amount of at least one stilbene compound to a patient in need of such treatment, said at least one stilbene compound having the formula (I):



wherein:

- R₁ represents

(i) the -CH_3 radical,


(ii) the radical $\text{-CH}_2\text{-O-R}_6$,

(iii) the radical -O-R_6 , or

(iv) the radical -CO-R_7 ,

wherein the radicals R_6 and R_7 have the meanings given below,

- Ar represents a radical selected from the group consisting of one of the radicals of formulae (a) to (f):



wherein R_8 and R_9 have the meanings given below,

- R_2 and R_3 , which may be identical or different, represent a hydrogen atom or a lower alkyl radical,

- R_4 represents the radical $\text{-(X)}_m\text{-(CH}_2)_n\text{-Y-(CH}_2)_p\text{-R}_{10}$,


the values m , n and p and the radicals X , Y and R_{10} having the meanings given below,

- R₅ represents a hydrogen or halogen atom, a lower alkyl radical or a radical

-O-R₆,

- R₆ represents a hydrogen atom, a lower alkyl radical or a radical -CO-R₁₁,

- R₇ represents a hydrogen atom, a lower alkyl radical, a radical -OR₁₂ or a radical



wherein R' and R'', which may be identical or different, represent a hydrogen atom, a lower alkyl radical, a mono- or polyhydroxyalkyl radical, or a phenyl radical optionally substituted with a substituent selected from the group consisting of a halogen atom, a hydroxyl radical, an alkyl radical, a nitro function, a methoxy group and an optionally substituted amine function, or alternatively, taken together, R' and R'' form a heterocycle,

wherein

- m is an integer equal to 0 or 1,

- n is an integer ranging from 1 to 6, inclusive,

- p is an integer ranging from 1 to 6, inclusive,

- X represents O or S(O)_q,

- Y represents O or S(O)_q,

- q is an integer ranging from 0 to 2, inclusive,

- R₈ represents a hydrogen or halogen atom, a lower alkyl radical or a radical

-O-R₆,

- R₉ represents a hydrogen atom, a lower alkyl radical or a radical -CO-R₁₁,

- R₁₀ represents a mono- or polyhydroxyalkyl radical wherein the hydroxyls are optionally protected in the form of methoxy, ethoxy, acetoxy or acetonide, a radical -CO-R₇ or a benzyl or phenethyl radical, optionally substituted with a substituent selected from the group consisting of a halogen atom, a hydroxyl, a nitro function and a methoxy group,

- R₁₁ represents a lower alkyl radical,

- R₁₂ represents a hydrogen atom, an alkyl radical, an alkenyl radical, a mono- or polyhydroxyalkyl radical in which the hydroxyls are optionally protected in the form of methoxy, ethoxy, acetoxy or acetonide, a phenyl radical optionally substituted with a substituent selected from the group consisting of a halogen atom, a hydroxyl radical, an alkyl radical, a nitro function, a methoxy group and an optionally substituted amine function, or a benzyl or phenethyl radical, optionally substituted with a substituent selected from the group consisting of a halogen atom, a hydroxyl, a nitro function and a methoxy group,

or a salt thereof, or an optical or geometrical isomer thereof.

27. (Currently Amended) ~~The method according to Claim 24, wherein the dermatological condition comprises~~ A method for the treatment of psoriasis, cutaneous atopy, respiratory atopy or gingival hypertrophy comprising administering an effective amount of at least one stilbene compound to a patient in need of such treatment, said at least one stilbene compound being selected from the group consisting of:

Ethyl 4-[(E)-2-(3-(1-adamantyl)-4-methoxyethoxy-methoxyphenyl)ethenyl]benzoate;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)ethenyl]benzoic acid;

Ethyl 4-[(E)-2-(3-(1-adamantyl)-4-methoxyethoxy-methoxyphenyl)-1-propenyl]benzoate;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-propenyl]benzoic acid;

4-[(Z)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-propenyl]benzoic acid;

Methyl 5-{2-[3-adamant-1-yl-4-(2-methoxyethoxy-methoxy)phenyl]propen-(E)-yl}pyridine-2-carboxylate;

5-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(E)-yl}pyridine-2-carboxylic acid;

5-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(Z)-yl}pyridine-2-carboxylic acid;

Ethyl 6-{2-[3-adamant-1-yl-4-(2-methoxyethoxymethoxy)phenyl]propen-(E)-yl}nicotinate;

6-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(E)-yl}nicotinic acid;

6-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(Z)-yl}nicotinic acid;

Methyl 4-{2-[3-adamant-1-yl-4-(2-methoxyethoxy-methoxy)phenyl]propen-(Z)-yl}-2-methoxybenzoate;

4-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(E)-yl}-2-methoxybenzoic acid;

4-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(Z)-yl}-2-methoxybenzoic acid;

Ethyl 4-{2-[3-adamant-1-yl-4-(3-ethoxymethoxypropyl)phenyl]propen-(E/Z)-yl}benzoate;

4-{2-[3-Adamant-1-yl-4-(3-ethoxymethoxypropyl)phenyl]propen-(E)-yl}benzoic acid;

4-{2-[3-Adamant-1-yl-4-(3-ethoxymethoxypropyl)phenyl]propen-(Z)-yl}benzoic acid;

Ethyl 4-{2-[3-adamant-1-yl-4-(3-benzyloxypropyl)-phenyl]propen-(E/Z)-yl}-benzoate;

4-{2-[3-Adamant-1-yl-4-(3-benzyloxypropyl)phenyl]-propen-(E)-yl}-benzoic acid;

4-{2-[3-Adamant-1-yl-4-(3-benzyloxypropyl)phenyl]-propen-(Z)-yl}benzoic acid;

Ethyl 4-{2-[3-adamant-1-yl-4-(3-diethylcarbamoyl-methoxypropyl)phenyl]propenyl}benzoate;

4-{2-[3-Adamant-1-yl-4-(3-diethylcarbamoylmethoxy-propyl)phenyl]propenyl}benzoic acid;

Ethyl 4-{2-[3-adamant-1-yl-4-(3-carboxymethoxy-propyl)phenyl]propenyl}benzoate;

4-{2-[3-Adamant-1-yl-4-(3-carboxymethoxypropyl)-phenyl]propenyl}benzoic acid;

Ethyl 4-{2-[3-adamant-1-yl-4-(3-carbamoylmethoxy-
propyl)phenyl]propenyl}benzoate;

4-{2-[3-Adamant-1-yl-4-(3-carbamoylmethoxypropyl)-phenyl]propenyl}benzoic
acid;

N-Ethyl-4-[(E)-2-(3-(1-adamantyl)-4-methoxyethoxy-methoxyphenyl)-1-
propenyl]benzamide;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-
propenyl]benzamide;

N-4-(Hydroxyphenyl)-4-[(E)-2-(3-(1-adamantyl)-
4-methoxyethoxymethoxyphenyl)-1-propenyl]benzamide;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-
propenyl]benzenemethanol;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-
propenyl]benzaldehyde;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-
propenyl]phenol;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-
propenyl]benzoic acid morpholide; and

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethyl-sulphanylphenyl)-1-
propenyl]benzoic acid.

28. (Currently Amended) ~~The method according to Claim 24, wherein the dermatological condition comprises~~ A method for the treatment of cutaneous psoriasis, mucous psoriasis, ungual psoriasis, psoriatic rheumatism, eczema,

respiratory atopy or gingival hypertrophy comprising administering an effective amount of at least one stilbene compound to a patient in need of such treatment, said at least one stilbene compound being selected from the group consisting of:

Ethyl 4-[(E)-2-(3-(1-adamantyl)-4-methoxyethoxy-methoxyphenyl)ethenyl]benzoate;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)ethenyl]benzoic acid;

Ethyl 4-[(E)-2-(3-(1-adamantyl)-4-methoxyethoxy-methoxyphenyl)-1-propenyl]benzoate;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-propenyl]benzoic acid;

4-[(Z)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-propenyl]benzoic acid;

Methyl 5-{2-[3-adamant-1-yl-4-(2-methoxyethoxy-methoxy)phenyl]propen-(E)-yl}pyridine-2-carboxylate;

5-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(E)-yl}pyridine-2-carboxylic acid;

5-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(Z)-yl}pyridine-2-carboxylic acid;

Ethyl 6-{2-[3-adamant-1-yl-4-(2-methoxyethoxymethoxy)phenyl]propen-(E)-yl}nicotinate;

6-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(E)-yl}nicotinic acid;

6-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(Z)-yl}nicotinic acid;

Methyl 4-{2-[3-adamant-1-yl-4-(2-methoxyethoxy-methoxy)phenyl]propen-(Z)-yl}-2-methoxybenzoate;

4-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(E)-yl}-2-methoxybenzoic acid;

4-{2-[3-Adamant-1-yl-4-(2-methoxyethoxymethoxy)-phenyl]propen-(Z)-yl}-2-methoxybenzoic acid;

Ethyl 4-{2-[3-adamant-1-yl-4-(3-ethoxymethoxypropyl)phenyl]propen-(E/Z)-yl}benzoate;

4-{2-[3-Adamant-1-yl-4-(3-ethoxymethoxypropyl)phenyl]propen-(E)-yl}benzoic acid;

4-{2-[3-Adamant-1-yl-4-(3-ethoxymethoxypropyl)phenyl]propen-(Z)-yl}benzoic acid;

Ethyl 4-{2-[3-adamant-1-yl-4-(3-benzyloxypropyl)-phenyl]propen-(E/Z)-yl}-benzoate;

4-{2-[3-Adamant-1-yl-4-(3-benzyloxypropyl)phenyl]-propen-(E)-yl}-benzoic acid;

4-{2-[3-Adamant-1-yl-4-(3-benzyloxypropyl)phenyl]-propen-(Z)-yl}benzoic acid;

Ethyl 4-{2-[3-adamant-1-yl-4-(3-diethylcarbamoylmethoxypropyl)phenyl]propenyl}benzoate;

4-{2-[3-Adamant-1-yl-4-(3-diethylcarbamoylmethoxypropyl)phenyl]propenyl}benzoic acid;

Ethyl 4-{2-[3-adamant-1-yl-4-(3-carboxymethoxy-propyl)phenyl]propenyl}benzoate;

4-{2-[3-Adamant-1-yl-4-(3-carboxymethoxypropyl)-phenyl]propenyl}benzoic acid;

Ethyl 4-{2-[3-adamant-1-yl-4-(3-carbamoylmethoxy-propyl)phenyl]propenyl}benzoate;

4-{2-[3-Adamant-1-yl-4-(3-carbamoylmethoxypropyl)-phenyl]propenyl}benzoic acid;

N-Ethyl-4-[(E)-2-(3-(1-adamantyl)-4-methoxyethoxy-methoxyphenyl)-1-propenyl]benzamide;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-propenyl]benzamide;

N-4-(Hydroxyphenyl)-4-[(E)-2-(3-(1-adamantyl)-4-methoxyethoxymethoxyphenyl)-1-propenyl]benzamide;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-propenyl]benzenemethanol;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-propenyl]benzaldehyde;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-propenyl]phenol;

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethoxy-phenyl)-1-propenyl]benzoic acid morpholide; and

4-[(E)-2-(3-(1-Adamantyl)-4-methoxyethoxymethyl-sulphanylphenyl)-1-propenyl]benzoic acid.